Enveda
Enveda uses AI to discover biologically active molecules from nature and develop them into small-molecule medicines for inflammatory and metabolic diseases.
$311MSeries E
ParticipantDC
Durable Capital Partners
Activity from announced rounds
Activity in this selectionUnited States · Oct 9, 2026 · Jan 1, 2026
- Rounds participated in
- 5
- Confirmed lead rounds
- 0 4 roles undisclosed
- New companies
- 5 First participation on record · 0 follow-on
- Funding in participating rounds
- $2.3B 5 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
5 in this selectionBaseten
Builds systems software for AI applications, powering inference and multi-model strategies
$1.5BSeries F
Role not disclosedHonest Health
Partners with health systems and providers on value-based care and risk models.
$140MSeries B
Role not disclosedSkyryse
Develops automated flight control systems for aircraft
$300MSeries C
Role not disclosedVieCure
Provides intelligent software platforms for oncology care
$43MUndisclosed
Role not disclosed